

Sunny Optical (2382 HK)

HSL/VLS recovery on track in June; Maintain BUY

Sunny reported June shipment data with MoM/YoY rebound for both handset lens (HLS) and vehicle lens (VLS), reversing YoY decline trend in past two months. We believe it was mainly driven by Samsung/Xiaomi restocking and automobile factory resumption in June. As stated in our upgrade note on 26 Jun, we believe Sunny is well positioned to gain share during downturn and regain growth sooner than peers in 2H20E. We suggest to accumulate the stock for demand recovery in 2H20E and 5G/video-driven upgrade trend in 2021. Maintain BUY with SOTP-based TP of HK\$148 (25.2x FY21E P/E).

- **HSL: MoM recovery to continue into 3Q20E.** Sunny reported 17% YoY/ 21% MoM growth for handset lens (HSL) in June, which rebounded from YoY/MoM decline in April and May. We believe this was driven by Samsung order recovery and Xiaomi restocking for 3Q20E. In contrast, Largan reported 1% YoY/ 7% MoM revenue growth in June, and expected flattish MoM shipment for July/August. We believe Sunny will outperform Largan with MoM recovery in 3Q20E given Samsung flagship restocking and share gain from Huawei.
- **HCM: Huawei and high-end demand remain weak in near term.** Given ongoing high-end weakness and de-spec trend on 5G models, Sunny's 3D sensing (other opto.) remained weak at 14% MoM in June (vs -31% MoM in May), while HCM slowed down to +1% YoY/ -9% MoM in June due to Huawei weakness in our view. Looking ahead, we expect HCM upgrade will re-accelerate in FY21E driven by 5G iPhone's 3D sensing adoption and lower 5G cost pressure in 2021. We estimate HCM/HLS ASP to rebound 14%/6% YoY to Rmb44.23/50.3 in FY21E (vs -7%/-1.2% YoY decline in FY20E).
- **VLS: 2Q delayed order to resume in 3Q20E.** Sunny's vehicle lens (VLS) posted +44% MoM/ -12% YoY in June, which continued recovery from +21% MoM/ -35% YoY in May. Given production resumption from overseas auto OEM since May, we expect 2Q20E delayed order will continue to support recovery in 3Q20E. Although Sunny's VLS YTD shipment of -9% YoY is still below FY20E growth target of 20% YoY, we are positive on demand recovery and opportunities in ADAS, LiDAR, HUD, smart headlights in 2021.
- **2H20 recovery on track; Maintain BUY.** We believe FY20E shipment weakness and de-spec impact are largely priced in, and we recommend to accumulate the stock for shipment recovery and upgrade trend in 2021. Maintain BUY and our SOTP-based TP of HK\$148 implies 25.2x FY21 P/E.

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	25,932	37,849	38,700	49,883	59,897
YoY growth (%)	15.9	46.0	2.2	28.9	20.1
Net income (RMB mn)	2,491	3,991	4,211	5,750	7,105
EPS (RMB)	2.3	3.65	3.85	5.26	6.49
YoY growth (%)	(14.6)	60.1	5.5	36.5	23.5
Consensus EPS (RMB)	NA	NA	4.21	5.44	6.66
P/E (x)	55.6	34.8	33.0	24.1	19.5
P/B (x)	14.7	10.8	8.5	6.5	5.1
Yield (%)	0.5	0.4	0.5	0.6	0.8
ROE (%)	26.8	31.4	25.8	27.1	26.1

Source: Company data, CMBIS estimates

BUY (Maintain)

Target Price	HK\$148.0
(Previous TP	HK\$148.0)
Up/Downside	+5%
Current Price	HK\$141.4

China Technology Sector

Alex Ng

(852) 3900 0881

alexng@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	159,043
Avg 3 mths t/o (HK\$ mn)	1,030.54
52w High/Low (HK\$)	151.00/ 77.60
Total Issued Shares (mn)	1,097

Source: Bloomberg

Shareholding Structure

SUN XU LTD	35.47%
JPMORGAN CHASE	4.50%
WENJIAN WANG	3.08%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	28.8%	20.1%
3-mth	25.7%	17.0%
6-mth	-0.4%	6.4%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Deloitte Touche Tohmatsu

Related Reports:


1. Sunny Optical (2382 HK) – Look beyond ongoing volatility; Upgrade to BUY on 2H recovery – 26 Jun 2020
2. Sunny Optical (2382 HK) – Call takeaways: Leadership intact despite clouded outlook – 25 Mar 2020
3. Sunny Optical (2382 HK) – Wait for better entry point – 18 Mar 2020

Please cast your valuable vote for CMBIS research team in the 2020 Asiamoney Brokers Poll:

<https://euromoney.com/brokers>


Focus Charts

Figure 1: Sunny Optical revenue trend



Source: Company data, CMBIS estimates

Figure 2: Sunny Optical revenue breakdown




Source: Company data, CMBIS

Figure 3: Handset front-cam upgrade trend




Source: Company data, CMBIS estimates

Figure 4: Sunny's target on next-gen camera




Source: Company data, CMBIS estimates

Figure 5: Sunny's packaging/processing capability



Source: Company data, CMBIS estimates

Figure 6: Sunny's automotive optical applications



Source: Company data, CMBIS estimates

Earnings forecasts

Figure 7: Major assumptions

	FY18	FY19	1H20E	2H20E	FY20E	FY21E	FY22E
Shipment volume (mn unit)							
Optical Components							
Handset lens sets	951	1,343	620	908	1,528	1,821	2,171
...YoY(%)	56%	41%	12%	15%	14%	19%	19%
Vehicle lens sets	40	50	21	32	52	65	81
...YoY(%)	25%	25%	-8%	15%	5%	24%	25%
Optoelectronic Products							
Handset camera modules	425	540	265	358	623	727	857
...YoY(%)	31%	27%	23%	10%	15%	17%	18%
Other optoelectronic (3D sensing)	10	49	18	29	46	55	65
...YoY(%)	27%	388%	-20%	5%	-6%	18%	20%
Revenue (Rmb mn)							
Optical Components	6,023	8,815	3,954	5,070	9,024	11,156	13,457
Optoelectronic Products	19,609	28,748	12,207	17,209	29,416	38,441	46,126
Optical instruments	300	285	134	126	260	286	314
Total Revenue	25,932	37,849	16,296	22,404	38,700	49,883	59,897
...YoY (%)	15.9%	46.0%	4.6%	0.6%	2.2%	28.9%	20.1%
Gross Margin							
Optical Components	41.5%	45.2%	44.0%	45.5%	44.8%	46.1%	46.3%
Optoelectronic products	8.4%	9.3%	8.3%	9.8%	9.2%	10.1%	10.4%
Optical instruments	40.5%	41.3%	41.0%	41.5%	41.2%	41.2%	41.2%

Source: Company data, CMBIS estimates

Figure 8: P&L forecast

RMB mn	FY18	1H19	2H19	FY19	1H20E	2H20E	FY20E	FY21E	FY22E
Revenue	25,932	15,575	22,274	37,849	16,296	22,404	38,700	49,883	59,897
...YoY	15.9%	30.0%	59.6%	46.0%	4.6%	0.6%	2.2%	28.9%	20.1%
Cost of sales	(21,019)	(12,711)	(17,387)	(30,098)	(13,009)	(17,724)	(30,732)	(39,298)	(46,989)
Gross profit	4,913	2,864	4,887	7,751	3,287	4,680	7,967	10,585	12,909
GPM (%)	18.9%	18.4%	21.9%	20.5%	20.2%	20.9%	20.6%	21.2%	21.6%
...YoY	2.3%	23.4%	88.5%	57.8%	14.8%	-4.2%	2.8%	32.9%	22.0%
SG&A	(644)	(388)	(541)	(929)	(440)	(543)	(983)	(1,247)	(1,497)
...% of rev	-2.5%	-2.5%	-2.4%	-2.5%	-2.7%	-2.4%	-2.5%	-2.5%	-2.5%
R&D	(1,362)	(827)	(1,383)	(2,209)	(864)	(1,344)	(2,208)	(2,893)	(3,474)
...% of rev	-5.3%	-5.3%	-6.2%	-5.8%	-5.3%	-6.0%	-5.7%	-5.8%	-5.8%
Operating profit	3,077	1,789	3,017	4,806	2,113	2,930	5,043	6,844	8,417
OPM (%)	11.9%	11.5%	13.5%	12.7%	13.0%	13.1%	13.0%	13.7%	14.1%
...YoY	-9.0%	18.3%	92.8%	56.2%	18.1%	-2.9%	4.9%	35.7%	23.0%
Net profit	2,491	1,431	2,560	3,991	1,715	2,496	4,211	5,750	7,105
NPM (%)	9.6%	9.2%	11.5%	10.5%	10.5%	11.1%	10.9%	11.5%	11.9%
...YoY	-14.2%	21.3%	95.3%	60.2%	19.8%	-2.5%	5.5%	36.5%	23.5%

Source: Company data, CMBIS estimates

Valuation

Maintain BUY with TP HK\$148.0

We maintain BUY rating with TP HK\$148. We derived our 12-month TP from SOTP valuation methodology and our new TP is based on weighted-average target P/E multiple of 25.2x FY21E EPS, in order to reflect 1) Sunny's diversification in multiple businesses with different growth profiles, and 2) visibility of product upcycles across different segments.

We assign 20x P/E to its CCM business, given its China No.1 position, product upcycle and advanced technology capacity. We assign 30x P/E for its vehicle lens business to reflect the high-margin and high-growth industry nature of vehicle lens (25% CAGR FY19-21E) and Sunny's No.1 global market share. We apply a 28x P/E to its handset lens segment given secular upgrade trend, continued share gains from peers and robust shipment momentum (18% sales CAGR FY19-21E).

Figure 9: Sunny Optical – SOTP valuation

Business segment	% of FY21E Profit	FY20E EPS (RMB)	Target P/E
Camera modules	36.6%	1.93	20x
Handset lenses	52.3%	2.75	28x
Vehicle lenses	10.1%	0.53	30x
Others	1.0%	0.05	25x
Total (RMB) /Implied P/E		5.26	25.2x
TP (HK\$)			148.0


Sources: Company data, CMBIS

Figure 10: Peers' valuation

Company	Ticker	Rating	Market Cap (US\$ mn)	Price (LC)	TP (LC)	Up/Down -side	P/E (x) FY20E	P/E (x) FY21E	P/B (x) FY20E	P/B (x) FY21E	ROE (%) FY20E	ROE (%) FY21E
Sunny Optical	2382 HK	Buy	20,011	141.4	148.0	5%	34.8	32.9	11.1	8.5	31.9	25.9
Q tech	1478 HK	Buy	1,818	12.0	14.8	23%	22.7	17.9	4.3	3.6	18.9	20.0
Cowell	1415 HK	NR	379	3.53	NA	NA	19.0	9.3	1.1	1.1	8.6	11.2
Truly	732 HK	NR	463	1.09	NA	NA	-	-	-	-	-	-
Catcher	2474 TT	NR	5,892	226.00	NA	NA	13.8	10.2	1.1	1.1	8.5	11.1
Largan	3008 TT	NR	18,203	4010.00	NA	NA	19.0	18.6	4.2	3.7	24.1	21.5
Lite-on	2301 TT	NR	3,697	46.70	NA	NA	11.7	12.2	1.5	1.4	12.1	11.5
Primax	4915 TT	NR	707	46.55	NA	NA	8.9	9.3	1.4	1.5	15.5	15.1
O-film	002456 CH	NR	7,976	20.72	NA	NA	106.8	43.1	6.1	5.1	5.9	11.8
Average							29.6	19.2	3.9	3.3	15.7	16.0


Source: Bloomberg, CMBIS

Figure 11: 12M forward P/E band



Source: Bloomberg, CMBIS

Figure 12: 12M forward P/B band



Source: Bloomberg, CMBIS

Financial Summary

Income statement

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	25,932	37,849	38,700	49,883	59,897
Cost of sales	(21,019)	(30,098)	(30,732)	(39,298)	(46,989)
Gross profit	4,913	7,751	7,967	10,585	12,909
Selling expenses	(210)	(279)	(295)	(399)	(479)
Admin expenses	(434)	(650)	(688)	(848)	(1,018)
R&D expenses	(1,362)	(2,209)	(2,208)	(2,893)	(3,474)
Other income	467	406	471	549	659
Other gain/ losses	(293)	(201)	(204)	(150)	(180)
Operating profit	3,077	4,806	5,043	6,844	8,417
Financial costs	(202)	(250)	(250)	(275)	(303)
Investment income	(24)	(6)	(6)	(6)	(6)
Pre-tax profit	2,851	4,550	4,787	6,563	8,108
Income tax expense	(339)	(531)	(548)	(774)	(957)
NCI	22	28	28	38	47
Net profit	2,491	3,991	4,211	5,750	7,105

Cash flow summary

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Profit before taxation	2,851	4,550	4,787	6,563	8,108
Depreciation/amortisation	819	1,171	1,191	1,509	1,828
Change in working capital	(203)	(1,213)	794	(2,665)	996
Others	100	152	(300)	(523)	(675)
Net cash from operating	3,568	4,662	6,473	4,885	10,256
Capex	(2,104)	(3,242)	(3,000)	(3,500)	(3,500)
Other	(3,395)	(314)	0	0	0
Net cash from investing	(5,499)	(3,556)	(3,000)	(3,500)	(3,500)
Net borrowings	88	0	0	0	0
Dividend paid	(725)	(623)	(657)	(898)	(1,109)
Purchase of shares	(78)	0	0	0	0
Other	3,672	(818)	(250)	(275)	(303)
Net cash from financing	2,957	(1,441)	(908)	(1,173)	(1,412)
Net change in cash	1,025	(336)	2,565	211	5,344
Cash at beginning of the year	1,227	2,254	1,917	4,482	4,694
Exchange difference	2	0	0	0	0
Cash at the end of the year	2,254	1,919	4,482	4,694	10,038

Balance sheet

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Current assets	16,768	22,446	21,108	32,537	33,220
Cash & equivalents	2,254	1,917	4,482	4,694	10,038
Financial assets	4,760	5,663	5,663	5,663	5,663
Deposits	235	21	21	21	21
Account receivables	6,231	9,630	6,588	14,316	10,785
Inventories	3,074	5,146	4,284	7,774	6,644
Other current assets	214	69	69	69	69
Non-current assets	6,084	8,247	10,059	12,088	13,795
Prepaid lease	214	0	0	0	0
PPE	4,523	6,567	8,376	10,366	12,039
Interest in associates	101	1	1	1	1
Other non-curr. assets	1,246	1,680	1,683	1,721	1,756
Total assets	22,852	30,693	31,167	44,626	47,016
Current liabilities	8,677	12,630	9,522	18,091	14,438
ST borrowings	1,482	1,119	1,119	1,119	1,119
Account payables	7,064	11,322	8,212	16,766	13,101
Other current liabilities	5,628	5,622	12,313	8,650	18,358
Non-current liabilities	4,887	5,336	5,336	5,336	5,336
LT borrowings	4,887	5,336	5,336	5,336	5,336
Others	4,887	5,336	5,336	5,336	5,336
Total liabilities	13,564	17,967	14,859	23,427	19,775
Share capital	105	105	105	105	105
Reserves	9,129	12,448	16,002	20,855	26,850
Minority interest	54	173	201	239	285
Shareholders' equity	9,288	12,726	16,308	21,198	27,241
Total equity & liabilities	22,852	30,693	31,167	44,626	47,016

Key ratios

YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Sales mix (%)					
Optical components	23.2	23.3	23.3	22.4	22.5
Optoelectronic products	75.6	76.0	76.0	77.1	77.0
Optical instruments	1.2	0.8	0.7	0.6	0.5
Growth (%)					
Revenue	15.9	46.0	2.2	28.9	20.1
Gross profit	2.3	57.8	2.8	32.9	22.0
Operating profit	(9.0)	56.2	4.9	35.7	23.0
Net profit	(14.2)	60.2	5.5	36.5	23.5
Profit & loss ratio (%)					
Gross margin	18.9	20.5	20.6	21.2	21.6
Operating margin	11.9	12.7	13.0	13.7	14.1
Net profit margin	9.6	10.5	10.9	11.5	11.9
Balance sheet ratio					
Net debt/total equity (x)	0.0	Net cash	Net cash	Net cash	Net cash
Current ratio (x)	1.9	1.8	2.2	1.8	2.3
Receivable turnover days	84	76.5	76.5	76.5	76.5
Inventory turnover days	49	49.8	56.0	56.0	56.0
Payable turnover days	115	111.5	116.0	116.0	116.0
Profitability (%)					
ROE	26.8	31.4	25.8	27.1	26.1
ROA	10.9	13.0	13.5	12.9	15.1
Per share data (RMB)					
EPS	2.28	3.65	3.85	5.26	6.49
DPS	0.66	0.57	0.60	0.82	1.01

Source: Company data, CMBIS estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US, institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.